WED 063 Eslicarbazepine acetate switch from carbamazepine or oxcarbazepine

    loading  Checking for direct PDF access through Ovid



To investigate eslicarbazapine acetate (ESL) in patients transitioning from carbamazepine or oxcarbazepine in clinical practice.


Euro-Esli was a pooled analysis of 14 European studies. Data were analysed for patients transitioning from carbamazepine and oxcarbazepine to ESL due to lack of efficacy or poor tolerability. Responder rate (≥50% seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit) were assessed after 3, 6 and 12 months of ESL treatment, and at last visit. Safety/tolerability analysis evaluated adverse events (AEs) and ESL discontinuation due to AEs.


Euro-Esli included 2058 patients; 233 (11.3%) transitioned from carbamazepine and 134 (6.5%) transitioned from oxcarbazepine. After 12 months, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n=163) were 70.0% and 30.9%, respectively. Corresponding values for patients transitioning from oxcarbazepine due to lack of efficacy (n=90) were 57.1% and 25.0%, respectively. Among patients who transitioned from carbamazepine (n=64) and oxcarbazepine (n=61) due to poor tolerability, 26.6% and 39.5% experienced AEs; 8.3% and 6.8% discontinued ESL due to AEs, respectively.


ESL may be a useful option for patients experiencing intolerable AEs or not achieving adequate control with carbamazepine or oxcarbazepine.


Supported by Eisai.

Related Topics

    loading  Loading Related Articles